Real-world outcomes of tafamidis in transthyretin amyloid cardiomyopathy.
Real-world data confirmed that tafamidis slowed progression of amyloid heart disease, sustaining benefits seen in clinical trials.
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive infiltrative cardiomyopathy associated with substantial morbidity and mortality. Las señales de alerta extracardiacas precedieron con frecuencia al diagnóstico cardiaco, lo que apoya una identificación precoz.
What the study was
- Study design
- Retrospective study
- Population
- Cancer/disease patients
- Category
- Prevention
- Maturity
- Exploratory
- Journal
- Archivos de cardiologia de Mexico
Why it surfaced
Matched topic(s): Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk. Study design: Retrospective study. Score 6/10.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.